Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitex suspends trial for pathogen inactivation system

This article was originally published in Clinica

Executive Summary

VI Technologies (Vitex) has suspended a phase III study of its Inactine blood pathogen inactivation system, after one of the patients in the trial developed an immune response to cells treated with the technology. The company said that pending further evaluation with the US FDA, no additional patients would be recruited to the study. Inactine is designed to inactivate viruses, bacteria and parasites in red blood cells.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts